Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Other financing activities: 2009-2022

Historic Other financing activities for BIO-TECHNE (TECH) over the last 12 years, with Sep 2022 value amounting to -$2.5 million.

  • BIO-TECHNE's Other financing activities rose 89.43% to -$2.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$16.2 million, marking a year-over-year decrease of 1079.63%. This contributed to the annual value of -$2.5 million for FY2023, which is 411.80% down from last year.
  • BIO-TECHNE's Other financing activities amounted to -$2.5 million in Q3 2022, which was down 172.26% from $3.4 million recorded in Q1 2022.
  • In the past 5 years, BIO-TECHNE's Other financing activities ranged from a high of $11.7 million in Q1 2021 and a low of -$23.2 million during Q3 2021.
  • Moreover, its 3-year median value for Other financing activities was $4.1 million (2020), whereas its average is $1.5 million.
  • Per our database at Business Quant, BIO-TECHNE's Other financing activities slumped by 2,149.48% in 2018 and then spiked by 1,133.33% in 2019.
  • BIO-TECHNE's Other financing activities (Quarterly) stood at $300,000 in 2018, then skyrocketed by 1,133.33% to $3.7 million in 2019, then rose by 29.73% to $4.8 million in 2020, then climbed by 27.08% to $6.1 million in 2021, then skyrocketed by 89.43% to -$2.5 million in 2022.
  • Its Other financing activities was -$2.5 million in Q3 2022, compared to $3.4 million in Q1 2022 and $6.1 million in Q4 2021.